Flonoltinib maleate is a small molecule compound primarily investigated for its potential therapeutic applications, particularly in the treatment of certain types of cancer. It acts as a selective inhibitor of specific kinases, which are enzymes that play crucial roles in cell signaling pathways related to cell growth and proliferation. The maleate salt form enhances its solubility and stability, making it more suitable for pharmaceutical formulations. In terms of its chemical structure, Flonoltinib features a complex arrangement of functional groups that contribute to its biological activity and specificity. The compound has undergone various preclinical and clinical studies to evaluate its efficacy and safety profile. As with many investigational drugs, its characteristics, including pharmacokinetics, metabolism, and potential side effects, are subjects of ongoing research. Overall, Flonoltinib maleate represents a promising avenue in targeted cancer therapy, reflecting the broader trend in oncology towards personalized medicine and the development of agents that can selectively inhibit tumor growth while minimizing damage to normal cells.

Flonoltinib maleate

2568842-57-7: Flonoltinib maleate is a small molecule compound primarily investigated for its potential therapeutic applications, particularly in the treatment of certain types of cancer. It acts as a selective inhibitor of specific kinases, which are enzymes that play crucial roles in cell signaling pathways related to cell growth and proliferation. The maleate salt form enhances its solubility and stability, making it more suitable for pharmaceutical formulations. In terms of its chemical structure, Flonoltinib features a complex arrangement of functional groups that contribute to its biological activity and specificity. The compound has undergone various preclinical and clinical studies to evaluate its efficacy and safety profile. As with many investigational drugs, its characteristics, including pharmacokinetics, metabolism, and potential side effects, are subjects of ongoing research. Overall, Flonoltinib maleate represents a promising avenue in targeted cancer therapy, reflecting the broader trend in oncology towards personalized medicine and the development of agents that can selectively inhibit tumor growth while minimizing damage to normal cells.

<p>Flonoltinib maleate is an orally active dual inhibitor of JAK2/FLT3, with IC50 values of 0.7 nM for JAK2, 4 nM for FLT3, 26 nM for JAK1, and 39 nM for JAK3. It exhibits anticancer properties.</p>

CAS 2568842-57-7

Flonoltinib maleate

Flonoltinib sulfate

Ref: TM-T204180